Advertisement

Organisation › Details
Greenovation Pflanzenbiotechnologie GmbH
greenovation Biotech GmbH is a specialty biopharmaceutical company developing customized protein biopharmaceuticals using its proprietary eukaryotic Physcomitrella-based BryoTechnologyTM-platform. Stable moss lines are developed for a sustainable, cGMP-compliant manufacturing of protein biopharmaceutical candidates. Key features of BryoTechnologyTM: photoautotrophic process: easy to cultivate in animal-derived-component-free and antibiotic-free purely mineral media ? rapid genome customization to express demanding proteins ? genetically stable genomic integration ? eukaryotic post-translational modifications; straightforward genetic glyco-engineering ? highly homogeneous glycosylation pattern ? targeted elimination of plant-type glyco-forms ? protein excretion into the media. Large scale production using the photoautotrophic moss lines is performed in certified, disposable bag-based reactors of the wave-type. Supply as well as full physico-chemical and biological characterization of GMP material for clinical has been established at greenovation's specialized partner companies. greenovation has two pre-clinical programs under development, in the area of orphan lysosomal storage diseases (LSD): Moss Alpha-Galactosidase for treating patients with Fabry Disease and Moss Glucocerebrosidase for treating patients suffering from Gaucher's Disease. With the Moss Alpha-Galactosidase program greenovation plans entering into a clinical phase I/IIa trial in the second half of 2014. *
![]() |
Start | 1999-09-01 established |
![]() |
End | renamed? |
Group | Eleva GmbH | |
Today | Eleva GmbH | |
Successor | Greenovation Biotech GmbH | |
![]() |
Industry | BIOTECH |
Industry 2 | recombinant protein production in plant cells | |
![]() |
Region | Freiburg im Breisgau |
Country | Germany | |
City | n. a. Freiburg im Breisgau | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2025-03-16 |
Advertisement

More documents for Eleva GmbH
- [1] Eleva GmbH. (9/19/24). "Press Release: Eleva Appoints Dr. Elisabeth Lackner to Its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization". Freiburg im Breisgau....
- [2] Eleva GmbH. (1/6/21). "Press Release: Eleva Secures up to EUR 60 Million to Advance a Drug Candidate, Appoints New Board Member". Freiburg....
- [3] Greenovation Biotech GmbH. (5/18/20). "Press Release: Elevating Future Therapies to a New Level. Greenovation Transforms into Eleva". Freiburg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top